Khosseĭn A, Mukharliamov N M, Mareev V Iu, Lobova N M, Ageev F T
Kardiologiia. 1988 Apr;28(4):54-8.
Sixteen patients on long-term treatment for primary pulmonary hypertension were studied. The results were compared after a single 20 mg dose, a two-week course and long-term (13.9 months on the average) use of the drug (40 mg/day). Pulmonary arterial catheterization, thermodilution and occlusion plethysmography were used. Changes in central and peripheral hemodynamic parameters were unidirectional and similar at all stages of the study. Nifedipine improved hemodynamics, as evidenced by selected criteria, in 80% of patients exposed to acute tests, in 91% after a course of treatment and in 58% after long-term use. Therefore, considering the ability of nifedipine to improve pulmonary hemodynamics as well as stable effect over more than one year of treatment, and the absence of marked side effects, this drug can be regarded as the most effective vasodilating agent for the treatment of primary pulmonary hypertension.
对16名接受原发性肺动脉高压长期治疗的患者进行了研究。在单次服用20毫克剂量、为期两周的疗程以及长期(平均13.9个月)使用该药物(40毫克/天)后,对结果进行了比较。采用了肺动脉导管插入术、热稀释法和阻塞体积描记法。在研究的所有阶段,中心和外周血流动力学参数的变化都是单向且相似的。硝苯地平改善了血流动力学,从选定标准来看,在接受急性试验的患者中有80%出现这种情况,经过一个疗程治疗后为91%,长期使用后为58%。因此,考虑到硝苯地平改善肺血流动力学的能力、超过一年治疗期的稳定效果以及无明显副作用,这种药物可被视为治疗原发性肺动脉高压最有效的血管扩张剂。